Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm Clinical Study of IL-15 Enhanced Engineered NK Cells for Refractory Relapsed/Metastatic Solid Tumors

NCT07621471 is registered in ClinicalTrials.gov with Genovn Therapeutics (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT07621471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07621471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm Clinical Study of IL-15 Enhanced Engineered NK Cells for Refractory Relapsed/Metastatic Solid Tumors
Lead sponsor
Genovn Therapeutics (Suzhou) Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
October 8, 2026
Completion date
December 31, 2028
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic cancer, solid tumors